Close Menu

    Subscribe to Updates

    Get the latest creative news from Healthradar about News,Health and Gadgets.

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    What's Hot

    Boston Scientific aims for market leadership in electrophysiology

    2. Oktober 2025

    Distalmotion adds hysterectomy indication; AiM raises funds for neurosurgical robot

    2. Oktober 2025

    GoodRx and Kroger Partner to Deliver Instant Brand Medication Savings

    2. Oktober 2025
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest Vimeo
    healthradar.nethealthradar.net
    • Home
    • Ai
    • Gadgets
    • Health
    • News
    • Contact Us
    Contact
    healthradar.nethealthradar.net
    Home»News»Boston Scientific aims for market leadership in electrophysiology
    News

    Boston Scientific aims for market leadership in electrophysiology

    HealthradarBy Healthradar2. Oktober 2025Keine Kommentare3 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    Boston Scientific aims for market leadership in electrophysiology
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Boston Scientific aims to become the market leader in the electrophysiology category as the device maker looks to pulsed field ablation to drive growth. 

    “Our new vision is not just to be a leader in pulsed field ablation, but to be a leader in overall electrophysiology,” Nick Spadea-Anello, Boston Scientific’s global president of electrophysiology, said at a Tuesday investor meeting. 

    PFA is a minimally invasive procedure where tissue is selectively scarred to treat atrial fibrillation, a common heart arrhythmia. The technology is expected to outpace other types of cardiac ablation because it can reduce the risk of damage to surrounding tissue and shorten procedure times. 

    Competition in the category has grown quickly as Boston Scientific, Medtronic and Johnson & Johnson have launched PFA devices in the U.S. Abbott received Europe’s CE Mark earlier this year for its own PFA device, and the company hopes to receive approval in 2026. 

    Spadea-Anello said that Boston Scientific has an advantage in being the first company to bring a PFA device to market. The company received a CE Mark for Farapulse in 2021. 

    Boston Scientific has treated 500,000 people to date with its Farapulse PFA system, Spadea-Anello said. 

    “This is significantly more than any other offering, to the tune of hundreds of thousands of more patients,” he claimed.

    Farapulse is the most prescribed PFA device, the executive added, and the company expects more growth as it adds new devices to its portfolio.

    J.P. Morgan analyst Robbie Marcus wrote in a research note that with continued leadership in atrial fibrillation ablation, indication expansion, and product rollouts in mapping and intracardiac imaging, “we think market leadership over the next few years is within reach.”

    Upcoming products, trials

    Boston Scientific executives highlighted new ablation catheters and mapping tools that they plan to launch in the coming years. A PFA catheter, called Farapoint, that allows electrophysiologists to create focal and linear-shaped lesions, is expected to launch before the end of the year.

    In 2027, Boston Scientific expects to launch a new version of its current Farawave PFA catheter. Spadea-Annello said the device will give physicians more information and precision, is more ergonomic and will feature enhanced contact sensing. In 2028, the company plans to launch a device called Faraflex, a large focal catheter that is designed for mapping and ablation.

    Boston Scientific also highlighted three clinical trials featuring its Farapulse platform, testing the system as a first-line treatment for persistent atrial fibrillation, in redo ablation procedures and as a treatment for ventricular tachycardia, Stifel analyst Rick Wise wrote in a research note.

    The company forecasts the global electrophysiology market to grow from an estimated $13 billion in 2025 to $20 billion in 2028.



    Source link

    aims Boston electrophysiology leadership Market Scientific
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleDistalmotion adds hysterectomy indication; AiM raises funds for neurosurgical robot
    ekass777x
    Healthradar
    • Website

    Related Posts

    News

    GoodRx and Kroger Partner to Deliver Instant Brand Medication Savings

    2. Oktober 2025
    News

    Plexāā Launches Wearable Device and App to Prepare Patients for Breast Surgery

    2. Oktober 2025
    News

    Omada Health Launches AI-Powered Meal Map to Transform Nutrition

    2. Oktober 2025
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    Garmin Venu 4: Everything we know so far about the premium smartwatch

    7. August 202566 Views

    The Top 3 Tax Mistakes High-Earning Physicians Make

    7. August 202524 Views

    Linea Expands AI-Powered Heart Failure Care Solution

    6. August 202519 Views

    Neurode wants to treat and track ADHD symptoms through a wearable headband

    1. Juni 20259 Views
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews

    Subscribe to Updates

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    About Us

    Welcome to HealthRadar.net — your trusted destination for discovering the latest innovations in digital health. We are dedicated to connecting individuals, healthcare professionals, and organizations with cutting-edge tools, applications

    Most Popular

    Garmin Venu 4: Everything we know so far about the premium smartwatch

    7. August 202566 Views

    The Top 3 Tax Mistakes High-Earning Physicians Make

    7. August 202524 Views
    USEFULL LINK
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    QUICK LINKS
    • Ai
    • Gadgets
    • Health
    • News
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    Copyright© 2025 Healthradar All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.